Rojas Juan I, Carnero Contentti Edgar, Henestroza Paula, Giachello Susana, Correale Jorge
Centro de Esclerosis Múltiple de Buenos Aires (CEMBA); Servicio de Neurología, Hospital Universitario de CEMIC.
Neuroimmunology Unit, Department of Neuroscience, Hospital Alemán, Buenos Aires, Argentina.
Mult Scler Relat Disord. 2021 Feb;48:102672. doi: 10.1016/j.msard.2020.102672. Epub 2020 Dec 10.
The objective was to evaluate the interval from first symptom of multiple sclerosis (MS) to diagnosis with the introduction of MS diagnostic criteria in a Latin American (LATAM) population.
Patients with relapsing-remitting MS (RRMS) completed a survey in 12 LATAM countries. Date of disease onset (first relapse) and date of diagnosis (confirmed disease) were required. Survival probabilities were evaluated for 5 diagnosis epoch groups: group 1: 1983-2000 Poser; group 2: 2001-2004 McDonald's first version; group 3: 2005-2009 revisions of 2005; group 4: 2010-2016 revisions of 2010; and group 5: 2017-2019 revisions of 2017.
1188 (75.6% females) patients were included. Mean time from disease onset to diagnosis in group 1 was 21 ± 8 months; in group 2, 19 ± 7 months; in group 3, 16 ± 10 months; in group 4, 9.6 ± 8.5 months; and in group 5, 8.2 ± 10 months. Significant differences were observed between groups 1, 2, 3 vs. 4 and 5 (p<0.001), while no differences were observed between groups 4 and 5 (p=0.08).
We observed a significant shortening of time from MS onset to diagnosis with the adoption of new diagnostic criteria in LATAM.
目的是评估拉丁美洲(LATAM)人群中从多发性硬化症(MS)首发症状到采用MS诊断标准进行诊断的时间间隔。
复发缓解型MS(RRMS)患者在12个拉丁美洲国家完成了一项调查。需要疾病发作日期(首次复发)和诊断日期(确诊疾病)。对5个诊断时期组的生存概率进行了评估:第1组:1983 - 2000年波泽标准;第2组:2001 - 2004年麦克唐纳第一版;第3组:2005 - 2009年2005年修订版;第4组:2010 - 2016年2010年修订版;第5组:2017 - 2019年2017年修订版。
纳入了1188例患者(75.6%为女性)。第1组从疾病发作到诊断的平均时间为21±8个月;第2组为19±7个月;第3组为16±10个月;第4组为9.6±8.5个月;第5组为8.2±10个月。第1、2、3组与第4、5组之间观察到显著差异(p<0.001),而第4组和第5组之间未观察到差异(p = 0.08)。
我们观察到在拉丁美洲采用新的诊断标准后,从MS发作到诊断的时间显著缩短。